Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Sunshine Biopharma, Inc. is a pharmaceutical company focused on the development and commercialization of oncology and other prescription drug products. The company operates in the biopharmaceutical and generic pharmaceuticals industries, with activities spanning drug research, licensing, and commercial distribution. Its business model combines early-stage drug development with revenue-generating generic pharmaceutical sales, primarily targeting institutional and specialty pharmacy customers.
The company’s primary revenue driver is its generic drug portfolio, while its proprietary pipeline is positioned as a longer-term value driver. Sunshine Biopharma’s strategic positioning is centered on leveraging cash flow from generics to support research and development in oncology. The company was founded in 2006 and initially focused on drug discovery; over time, it evolved into a hybrid model through the acquisition and expansion of commercial-stage generic pharmaceutical operations.
Business Operations
Sunshine Biopharma conducts its operations through distinct business units, including Nora Pharma Inc., which serves as the company’s generic pharmaceutical subsidiary. Through this unit, the company markets and distributes FDA-approved generic prescription drugs, including products used in oncology and other therapeutic areas. Revenue is primarily generated from product sales to wholesalers, distributors, hospitals, and pharmacies, predominantly in the United States.
In addition to its commercial operations, the company maintains a drug development program focused on proprietary small-molecule anticancer compounds. Research and development activities are conducted through a combination of internal management and external contract research organizations. Manufacturing for both generic and development-stage products is largely outsourced to third-party partners, including facilities located outside the United States, consistent with industry practice.
Strategic Position & Investments
Strategically, Sunshine Biopharma aims to balance near-term revenue stability with longer-term growth from intellectual property–based drug candidates. The company has invested in building a diversified generic drug portfolio while continuing to advance its proprietary oncology assets through preclinical evaluation. This dual-track approach is intended to mitigate the high risk and long timelines associated with drug development.
A key strategic investment was the acquisition and expansion of Nora Pharma Inc., which significantly shifted the company toward commercial-stage operations. The company has indicated ongoing interest in acquiring or licensing additional generic products and complementary pharmaceutical assets. Its emerging technology focus remains centered on novel anticancer mechanisms, although development remains at an early stage and outcomes are uncertain based on available public disclosures.
Geographic Footprint
Sunshine Biopharma is headquartered in Fort Lauderdale, Florida, with additional corporate and operational presence in Canada through Sunshine Biopharma Canada Inc. The company’s primary commercial market is North America, particularly the United States, where most of its generic drug sales occur.
Internationally, the company maintains relationships with third-party manufacturers and suppliers in Asia, including India, supporting cost-efficient production of pharmaceutical products. While Sunshine Biopharma does not report extensive direct international sales operations outside North America, its supply chain and regulatory strategy reflect a global operational footprint typical of small-cap pharmaceutical companies.
Leadership & Governance
Sunshine Biopharma is led by an executive team with experience in pharmaceuticals, finance, and drug development. The company emphasizes a governance approach focused on capital discipline, regulatory compliance, and the integration of commercial and research-driven strategies. Public disclosures emphasize management’s intent to create shareholder value through disciplined growth and selective investment.
Key executives include:
- Steve Slilaty – President and Chief Executive Officer
- Christopher Giordano – Chief Financial Officer
- Pallavi Raghuram – Head of Research and Development
Information on broader leadership depth and succession planning is limited in publicly available sources, and some executive role details are not consistently disclosed across filings.